Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients

Department of Psychology, University of Iowa, Iowa City, IA 52242, USA.
Brain Behavior and Immunity (Impact Factor: 6.13). 10/2010; 25(2):250-5. DOI: 10.1016/j.bbi.2010.10.012
Source: PubMed

ABSTRACT Noradrenergic pathways have been implicated in growth and progression of ovarian cancer. Intratumoral norepinephrine (NE) has been shown to increase with stress in an animal cancer model, but little is known regarding how tumor NE varies with disease stage and with biobehavioral factors in ovarian cancer patients. This study examined relationships between pre-surgical measures of social support, depressed mood, perceived stress, anxiety, tumor histology and tumor catecholamine (NE and epinephrine [E]) levels among 68 ovarian cancer patients. We also examined whether associations observed between biobehavioral measures and tumor catecholamines extended to other compartments. Higher NE levels were found in advanced stage (p=0.006) and higher grade (p=0.001) tumors. Adjusting for stage, grade, and peri-surgical beta blockers, patients with a perceived lack of social support had significantly higher tumor NE (β=-0.29, p=0.012). A similar trend was seen for social support and ascites NE (adjusting for stage, peri-surgical beta blockers and caffeine: β=-0.50, p=0.075), but not for plasma NE. Other biobehavioral factors were not related to tumor, ascites, or plasma NE (p values >0.21). Tumor E was undetectable in the majority of tumors and thus E was not further analyzed. In summary, these results suggest that tumor NE provides distinct information from circulating plasma concentrations. Tumor NE levels were elevated in relationship to tumor grade and stage. Low subjective social support was associated with elevated intratumoral NE. As beta-adrenergic signaling is related to key biological pathways involved in tumor growth, these findings may have implications for patient outcomes in ovarian cancer.

Download full-text


Available from: Frank Penedo, Aug 28, 2014
  • Source
    • "Variance comes from the heterogeneity of sample sizes (Ns are noted below), analyses of subgroups within larger trials, intervention components, and differential rates of follow-up, among other factors, which makes generalizations difficult. The majority of trials noted below studied breast cancer patients , and there are only limited data from patients with other types of cancer (i.e., ovarian, Lekander, Fürst, Rotstein , Hursti, & Fredrikson, 1997; prostate, Cohen et al., 2011; melanoma, Fawzy, Kemeny, et al., 1990; cervical, Lutgendorf et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the last decade, there have been groundbreaking strides in our understanding of the multiple biological pathways by which psychosocial and behavioral factors can affect cancer progression. It is now clear that biobehavioral factors not only affect cellular immunity but both directly and indirectly modulate fundamental processes in cancer growth, including inflammation, angiogenesis, invasion, and metastasis. There is also an emerging understanding of how psychological and behavioral factors used in interventions can impact these physiological processes. This review outlines our current understanding of the physiological mechanisms by which psychological, social, and behavioral processes can affect cancer progression. The intervention literature is discussed, along with recommendations for future research to move the field of biobehavioral oncology forward. (PsycINFO Database Record (c) 2015 APA, all rights reserved).
    American Psychologist 02/2015; 70(2):186-197. DOI:10.1037/a0035730 · 6.87 Impact Factor
  • Source
    • "This has a variety of psychosocial implications. For instance, poor levels of perceived social support are associated with higher levels of VEGF and IL-6 (Lutgendorf et al., 2011). Musselman et al. (2001b) found in cancer patients that higher than normal plasma IL-6 concentrations were associated with a diagnosis of depression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Depression, ranging from mild to severe, is the most frequently found psychological symptom among individuals with cancer. Depression in cancer patients has been known to mitigate emotional distress, quality of life, adherence to medical treatment, and overall health outcomes. Specifically, depression has been associated with impaired immune response and with poorer survival in patients with cancer. Various studies have found that psychotherapeutic interventions are effective in reducing symptoms of depression, which in turn could affect disease progression and mortality. This paper provides updated information on psychotherapeutic interventions geared towards cancer patients suffering from depressive disorders, and its impact on disease progression. PubMed, Cochrane Library database, PsycINFO and PsycARTICLES databases were searched from January 1980 through August 2013 using key words: psychotherapy, treatment, oncology, cancer, psycho-oncology, psychosocial issues, psychosocial stress, depression, mood disorder, and psychoneuroimmunology.
    International Review of Psychiatry 02/2014; 26(1):31-43. DOI:10.3109/09540261.2013.864259 · 1.80 Impact Factor
  • Source
    • "It has been demonstrated that high level of stress stimulation could contribute to disease progression, including various kinds of cancer. The stress derived from social isolation was found to elevate the tumour noradrenaline level in ovarian cancer patients, and its level was correlated with tumour grades and stages [21]. A growing body of investigations have suggested that stress hormones adrenaline and/or noradrenaline exhibit a tumour-promoting function in a variety of tumour types including but not limited to the cancers of pancreas [22], breast [23], ovary [24] [25], colorectum [26], oesophagus [27], lung [28] [29], prostate [30], nasopharynx [31], melanoma [32], leukaemia [33] [34], even hemangioendotheliom and angiosarcoma [35]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: β-Adrenoceptors are broadly distributed in various tissues of the body. Stress hormones regulate a panel of important physiological functions and disease states including cancer. Nicotine and its derivatives could stimulate the release of stress hormones from cancer cells, leading to the promotion of cancer development. β-blockers have been widely used to control hypertension for decades. Recently, these agents could have significant implications in cancer therapy through blockade of adrenoceptors in tumor tissues. In this review, we summarize recent advancements about the influence of stress hormones, nicotine and β-adrenoceptors on cancer cell proliferation, apoptosis, invasion and metastasis, and also tumor vasculature normalization. Relevant signal pathways and potential value of β-blockers in the treatment of cancer are also discussed in this review.
    Seminars in Cancer Biology 09/2013; 23(6). DOI:10.1016/j.semcancer.2013.08.009 · 9.33 Impact Factor
Show more